AstraZeneca, BI Avoid Questions On Copay Assistance

By Luke Zarzecki / August 14, 2025 at 1:49 PM

AstraZeneca and Boehringer Ingelheim are keeping details and their future plans for copay assistance close to their chest as the Maryland Prescription Drug Affordability Board (PDAB) considers putting an upper payment limit on their drugs, which some patient groups are concerned could lead the drug companies to yank their assistance programs from the state.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.